CompletedNCT03736057
Genetic Evaluation for Medication Selection (GEMS) Study
Studying Genetic dementia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Alabama at Birmingham
- Principal Investigator
- David Geldmacher, MDUniversity of Alabama at Birmingham
- Intervention
- Delayed results of pharmacogenomic results(other)
- Enrollment
- 40 target
- Eligibility
- 50 years · All sexes
- Timeline
- 2016 – 2018
Study locations (1)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03736057 on ClinicalTrials.govOther trials for Genetic dementia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06641726Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental IllnessAkrivia Health
- RECRUITINGNCT06703541ADRC Clinical Cohort (Alzheimer's Disease)Duke University
- RECRUITINGNCT02014246Genetic Characterization of Movement Disorders and DementiasNational Institute on Aging (NIA)
- RECRUITINGNCT00064870Alzheimer's Disease Genetics StudyIndiana University